Abstract
Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a need to develop targeted therapies to enable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor α (IL-7Rα) signaling pathways are prime therapeutic targets because these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7Rα signaling pathways may lead to improved outcomes in a subset of patients.
Publication types
-
Review
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Humans
-
Interleukin-7 / antagonists & inhibitors*
-
Interleukin-7 / metabolism
-
Neoplasm Proteins / antagonists & inhibitors*
-
Neoplasm Proteins / metabolism
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
-
Signal Transduction / drug effects*
Substances
-
IL7 protein, human
-
Interleukin-7
-
Neoplasm Proteins